Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Rain Therapeutics (NasdaqGS: RAIN) announced three poster presentations at the 2022 ASCO Annual Meeting, focusing on their oral MDM2 inhibitor, milademetan. The presentations will cover:
- Using CDKN2A loss to predict sensitivity (Abstract 3136)
- MANTRA: A phase 3 study of milademetan vs. trabectedin in dedifferentiated liposarcomas (Abstract TPS11589)
- MANTRA-2: A phase 2 study in TP53-wild type tumors (Abstract TPS3165)
All posters will be available on the Rain website following the event.
- None.
- None.
NEWARK, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 3–7, 2022.
Additional presentation details can be found below:
| Title: | Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan | |
| Abstract Number: | 3136 | |
| Presenter: | Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA | |
| Poster Session: | Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology | |
| Poster Number: | 128 | |
| Date/Time: | Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT |
| Title: | MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with dedifferentiated liposarcomas | |
| Abstract Number: | TPS11589 (Trial in Progress Poster) | |
| Presenter: | Mrinal M. Gounder, M.D., Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College | |
| Poster Session: | Sarcoma | |
| Poster Number: | 489b | |
| Date/Time: | Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT |
| Title: | MANTRA-2: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors | |
| Abstract Number: | TPS3165 (Trial in Progress Poster) | |
| Presenter: | Ecaterina Elena Dumbrava, M.D., The University of Texas MD Anderson Cancer Center | |
| Poster Session: | Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology | |
| Poster Number: | 149b | |
| Date/Time: | Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT |
Copies of each poster will be available by visiting the "Events" section of the Rain website after the conclusion of the presentations and will be archived on the Rain website.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com
FAQ
What is the significance of Rain Therapeutics' presentations at ASCO 2022?
When and where is the ASCO 2022 Annual Meeting being held?
What topics will be covered in the posters presented by Rain Therapeutics?
When will the posters from Rain Therapeutics be available to the public?
What is milademetan and why is it important for Rain (RAIN)?
